Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study
about
Update on Clinical Trials in Dry Age-related Macular DegenerationGeographic atrophy in patients with advanced dry age-related macular degeneration: current challenges and future prospectsCurrent therapeutic developments in atrophic age-related macular degenerationGenetic variants in the complement system predisposing to age-related macular degeneration: a reviewThe stereotypical molecular cascade in neovascular age-related macular degeneration: the role of dynamic reciprocityRecent developments in the management of dry age-related macular degenerationThe Project MACULA Retinal Pigment Epithelium Grading System for Histology and Optical Coherence Tomography in Age-Related Macular DegenerationDelayed Rod-Mediated Dark Adaptation Is a Functional Biomarker for Incident Early Age-Related Macular Degeneration.Zinc supplementation inhibits complement activation in age-related macular degeneration.Clinical characteristics and current treatment of age-related macular degeneration.Fundus autofluorescence characteristics of nascent geographic atrophy in age-related macular degenerationGrowth of geographic atrophy in the comparison of age-related macular degeneration treatments trials.Age-Related Macular Degeneration: A Disease of Systemic or Local Complement Dysregulation?Connecting the innate and adaptive immune responses in mouse choroidal neovascularization via the anaphylatoxin C5a and γδT-cells.A local complement response by RPE causes early-stage macular degeneration.Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials.Applying complement therapeutics to rare diseases.A novel bispecific molecule delivered by recombinant AAV2 suppresses ocular inflammation and choroidal neovascularizationRecent advances in the management of dry age-related macular degeneration: A review.Age-related macular degeneration: genome-wide association studies to translation.Visual Function in Older Eyes in Normal Macular Health: Association with Incident Early Age-Related Macular Degeneration 3 Years Later.Targeting the complement system for the management of retinal inflammatory and degenerative diseases.The role of the complement system in age-related macular degeneration.Recent developments in the treatment of age-related macular degeneration.Drugs in Phase II clinical trials for the treatment of age-related macular degeneration.Highly penetrant alleles in age-related macular degeneration.GEOGRAPHIC ATROPHY: Semantic Considerations and Literature Review.Phenotype Characteristics of Patients With Age-Related Macular Degeneration Carrying a Rare Variant in the Complement Factor H Gene.Complement Activation and Inhibition in Retinal Diseases.Stem Cell-Based Therapy for Diseases of the Retinal Pigment Epithelium: From Bench to Bedside.Dry Age-Related Macular Degeneration Pharmacology.THE PATHOPHYSIOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION AND THE COMPLEMENT PATHWAY AS A THERAPEUTIC TARGET.The complement system in age-related macular degeneration: A review of rare genetic variants and implications for personalized treatment.Therapeutic complement inhibition: a promising approach for treatment of neuroimmunological diseases.From compliment to insult: genetics of the complement system in physiology and disease in the human retina.A Novel Complotype Combination Associates with Age-Related Macular Degeneration and High Complement Activation Levels in vivo.Role of Factor H and Related Proteins in Regulating Complement Activation in the Macula, and Relevance to Age-Related Macular Degeneration.Current drug and molecular therapies for the treatment of atrophic age-related macular degeneration: phase I to phase III clinical development.An Induced Pluripotent Stem Cell Patient Specific Model of Complement Factor H (Y402H) Polymorphism Displays Characteristic Features of Age-Related Macular Degeneration and Indicates a Beneficial Role for UV Light Exposure.Advances in Age-related Macular Degeneration Understanding and Therapy.
P2860
Q26767098-E173377E-1EF1-4015-B957-ACAD36FDBEC8Q26774188-67D82B67-99ED-45DD-90F2-15FCC08824A7Q26778247-82C16628-2662-49A8-8365-E859FA5D2803Q27021836-B9B56E8B-DC41-43B8-BF2E-192073AF88C4Q28085495-E8F1E884-0367-47C2-95EA-516FD412CAF3Q28088816-2CCAEE78-7151-45FA-AD81-84E0540BF564Q28645952-572DF30C-1780-4664-8800-43555F1A8501Q34500095-8EF77E2D-E338-4885-88DC-C7B979ABC02FQ34506404-BD7B97DB-1131-4E70-A7AF-5DFFD5B41022Q34930298-CC4DB780-C151-4AD5-9EBE-A850EA68E4A8Q35145864-1DC6E83C-142E-4476-95F3-DC5E969D4AB3Q35214092-DF99A882-83B5-4146-9B8E-E5F2B84CC531Q35750545-2C5BF57E-3194-4953-8F9C-BBD90217D2EEQ35974464-8C78D86D-B2DF-4A43-85C1-CE3A24DC589BQ36065466-70C0B61B-271B-470D-BE2A-D11A4FE8DCFDQ36247080-0C6C1FD1-4166-43B1-8D3D-38044CC6095DQ36315497-DE94AA0B-6C9B-482E-9D90-650DC328B8CEQ36319263-8DBF021D-E447-40FD-A6F6-1421B9649E36Q36377333-5CB2D43B-3394-4FF4-9609-3BB00F208483Q36773888-123FA615-5419-49F3-9003-0368E794476FQ36848556-7E56EFC5-0A37-40C0-BBD3-B76D214D305FQ37262287-B2B12DF2-C839-4617-BBBC-51D63D3CE4E5Q37646779-9C1D1CA5-EB9E-4BAE-B9CE-AC5A0FCC11F7Q37679956-5BDFF18D-2957-4601-9CB3-0294E8571241Q38253067-88B6B03A-2BB4-4274-AC4B-B7F26DF371DBQ38265848-D3287ED1-DBD6-4970-ADED-4548FEAE668AQ38388508-8DF8365A-CC4D-4689-B490-170010C319F9Q38599697-22603661-7F67-4BD7-84C6-77EA39A77876Q38616354-F39DD111-08CD-4E4C-B826-67228D1E262EQ38766799-E60658B5-D466-4E63-BDF2-6C99CECCB7D3Q38789140-5C6119B5-F10D-4E24-9A28-38EDB4A74369Q39024579-3BCC862C-C909-4BF6-AB8C-33843E841AE2Q39034874-1A52420D-F01B-4D7A-981D-AF45DC1B74F5Q39090725-83CD21EB-C042-45AA-93C3-47513C84A1E2Q39290950-25DA8781-D16A-4C99-9EF1-357292DDC8A7Q42119687-2E93B3CA-E011-4645-AF61-299DA1BE08ADQ43162540-61253E86-3317-413B-AE4F-9EBC7FBBD758Q45870879-B52E343F-62C9-49B0-B69C-A6E7BA8C4374Q47123727-5525B0D6-AD01-4A6A-920D-0843E64AC87BQ47427948-CE39F18E-5613-486A-A981-0C975D9A3A29
P2860
Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Systemic complement inhibition ...... generation: the COMPLETE study
@ast
Systemic complement inhibition ...... generation: the COMPLETE study
@en
Systemic complement inhibition ...... eneration: the COMPLETE study.
@nl
type
label
Systemic complement inhibition ...... generation: the COMPLETE study
@ast
Systemic complement inhibition ...... generation: the COMPLETE study
@en
Systemic complement inhibition ...... eneration: the COMPLETE study.
@nl
prefLabel
Systemic complement inhibition ...... generation: the COMPLETE study
@ast
Systemic complement inhibition ...... generation: the COMPLETE study
@en
Systemic complement inhibition ...... eneration: the COMPLETE study.
@nl
P2093
P2860
P1433
P1476
Systemic complement inhibition ...... generation: the COMPLETE study
@en
P2093
Andrew A Moshfeghi
Carlos Alexandre de Amorim Garcia Filho
Fernando M Penha
Giovanni Gregori
Kang Zhang
Philip J Rosenfeld
Renata Portella Nunes
Srinivas Sadda
William Feuer
Zohar Yehoshua
P2860
P304
P356
10.1016/J.OPHTHA.2013.09.044
P577
2013-11-26T00:00:00Z